Latest News

Latest News

What a Hospitalist’s Floor Sees That Health AI Doesn’t

What a Hospitalist’s Floor Sees That Health AI Doesn’t

Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...

read more
Licensing versus Acquisition: How Pharma Chooses

Licensing versus Acquisition: How Pharma Chooses

On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Welcome to Life Science Daily News

Welcome to Life Science Daily News

Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...

read more
Decision Frameworks in Pharma

Decision Frameworks in Pharma

Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...

read more
Durvalumab approved in the US

Durvalumab approved in the US

Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...

read more
Novartis to Acquire Avidity in $12B RNA Therapy Deal

Novartis to Acquire Avidity in $12B RNA Therapy Deal

The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...

read more
Ground-Breaking Gene Therapy for Hunter Syndrome

Ground-Breaking Gene Therapy for Hunter Syndrome

Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....

read more
AstraZeneca and Sun Pharma Join Forces in India

AstraZeneca and Sun Pharma Join Forces in India

AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...

read more
Welcome to Life Science Daily News

Welcome to Life Science Daily News

Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...

read more
Decision Frameworks in Pharma

Decision Frameworks in Pharma

Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...

read more
Durvalumab approved in the US

Durvalumab approved in the US

Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...

read more
Novartis to Acquire Avidity in $12B RNA Therapy Deal

Novartis to Acquire Avidity in $12B RNA Therapy Deal

The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...

read more
Ground-Breaking Gene Therapy for Hunter Syndrome

Ground-Breaking Gene Therapy for Hunter Syndrome

Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....

read more
AstraZeneca and Sun Pharma Join Forces in India

AstraZeneca and Sun Pharma Join Forces in India

AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Remote Stroke Surgery Breakthrough with New Robotic System

Remote Stroke Surgery Breakthrough with New Robotic System

In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...

read more
The Passing of a Scientific Giant: James D. Watson

The Passing of a Scientific Giant: James D. Watson

Renowned molecular biologist James D. Watson has died at the age of 97, his son and the Cold Spring Harbor Laboratory (CSHL) in New York confirmed. The scientist, best known for co-discovering the double helix structure of DNA in 1953, passed away following a brief...

read more
Rewriting the MND Playbook

Rewriting the MND Playbook

How AI and Biomarkers Are Accelerating the Fight Against Motor Neurone Disease Every ninety minutes in the United Kingdom, someone receives a diagnosis of Motor Neurone Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS), and every ninety minutes, someone...

read more
Challenges in Life Sciences Real Estate

Challenges in Life Sciences Real Estate

The commercial real estate market serving the life sciences industry is currently undergoing a complex period of adjustment. The underlying dynamics that once propelled rapid growth, such as enthusiastic venture capital, strong demand from biotech and pharmaceutical...

read more

Further News

Weekly News Roundup | 13 July 2026

Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...

Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...

The Next Public Health Playbook: Why Trust Matters More Than Ever

The current news cycle is dominated by new and exotic-sounding organisms and chemicals: PFOS, bisphenols, phthalates, Mpox, New World screwworm, Andes hantavirus, Ebola bundibugyo, Borrelia burgdorferi, dengue, and chikungunya. What do they have in common? They are...

Clinical Trials Roundup | 10 July 2026

Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...

Adipose Tissue Isn’t Just Storage: Fat as an Endocrine and Immune Organ

For much of the 20th century, body fat was viewed mainly as the body's energy reservoir—a passive tissue that stored excess calories for future use. While this remains an important function of adipose tissue, research over the past few decades has revealed a far more...

FDA Drug Approval Decisions to Watch: July and August 2026

The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...

New Research On the Next Phase in Protecting Muscle During GLP-1 Treatment

When I wrote previously for this publication about the gap between GLP-1 prescribing rates and the clinical conversation around lean muscle preservation, the argument centred on a simple premise: weight loss is not fat loss, and the clinical infrastructure around...

Atacicept FDA Approval: Trutakna Cleared for IgAN

The atacicept FDA approval that the nephrology community had been anticipating since January arrived on schedule on 7 July 2026, when the US Food and Drug Administration granted accelerated approval to Vera Therapeutics' atacicept-vymj, to be marketed as Trutakna, for...

AI Trust in Healthcare Starts with the People in the Room

Healthcare is on an accelerated path to digitisation, creating real opportunity to reduce administrative burden, improve risk detection, support prioritisation, and help people access the right care sooner. But without deliberate design, these same systems risk...

The Regulatory Window for AI in Pharmacovigilance Is Open

In more than two decades of working with global CROs, pharmaceutical companies, and biotech organizations, I have watched pharmacovigilance teams absorb wave after wave of increasing complexity. More products on the market. More data sources to monitor. More...

Webinar: Decoding Neurodegeneration via iPSC-Derived Human Brain Models

The human brain presents an intricate evolutionary paradox. While its sophisticated neural networks govern complex cognition, its architecture is uniquely susceptible to progressive degradation. For decades, the biomedical community has grappled with an uncomfortable...

Why the Immune System Is Becoming the New Battlefield in Cancer Care

The Old Paradigm For more than a century, cancer treatment has been defined by a straightforward objective: find the tumor and destroy it. Surgery removes it, radiation damages it. Chemotherapy attacks rapidly dividing cells. These approaches have saved countless...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.